Eli Lilly, Nordisk seek expanded pleading bar in US case over GLP-1 drugs, Texas, Louisiana say
MLex Summary: The attorneys general for Texas and Louisiana told a US federal judge that accepting Eli Lilly and Novo Nordisk’s motion to dismiss antitrust claims over GLP-1 drugs would heighten...To view the full article, register now.
Already a subscriber? Click here to view full article